Marengo to Present Initial Results from Invikafusp Alfa and TRODELVY® Combination Study, STARt-002, at the 2025 San Antonio Breast Cancer Symposium

Safety profile of Invikafusp alfa + TRODELVY® is consistent with the known profiles of each agent Invikafusp alfa demonstrates selective expansion of Vβ6/10 T cells when combined with TRODELVY® in previously treated metastatic breast cancer Early anti-tumor activity observed in majority...

Read More